Nexus Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 24 Year, 5 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.11 Cr
- Revenue Growth -41.60%
- Profit Growth 23.09%
- Ebitda -11.00%
- Net Worth 0.61%
- Total Assets -11.68%
About Nexus Drugs
Nexus Drugs Private Limited (NDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 02 February 2001 and has a history of 24 years. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹2.11 Cr.
Suresh Kilaru, Ramakrishna Gadipudi, and Mallikarjun Koyilakonda serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24243TG2001PTC036160
-
Company No.
036160
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Feb 2001
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Nexus Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Kilaru
|
Director | 13-Aug-2020 | Current |
|
Ramakrishna Gadipudi
|
Director | 08-Feb-2017 | Current |
| Mallikarjun Koyilakonda | Director | Current |
Financial Performance of Nexus Drugs.
Nexus Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.6% decrease. The company also saw a substantial improvement in profitability, with a 23.09% increase in profit. The company's net worth moved up by a moderate rise of 0.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexus Drugs?
In 2023, Nexus Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rajan Dairy LlpSuresh Kilaru is a mutual person
-
Reyan Buildwell India Private Limited
Suresh Kilaru is a mutual person
-
Elite Electoral Calculus Private Limited
Suresh Kilaru is a mutual person
-
Sonalini Secure Print Private Limited
Ramakrishna Gadipudi is a mutual person
-
Svr Pharmatech Private Limited
Ramakrishna Gadipudi is a mutual person
-
Svr Api Private Limited
Ramakrishna Gadipudi is a mutual person
Charges (Loans)
₹2.11 Cr
₹0
Charges Breakdown by Lending Institutions
- Andhra Bank : 2.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Feb 2012 | Andhra Bank | ₹1.11 Cr | Open |
| 22 Dec 2009 | Andhra Bank | ₹1.00 Cr | Open |
How Many Employees Work at Nexus Drugs?
Unlock and access historical data on people associated with Nexus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexus Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
